AFT Pharma: FY27 revenue expected to hit $300M, positive iron IV results in

AFT Pharmaceuticals (ASX:AFP) founder and CEO Hartley Atkinson joined HotCopper to discuss the company’s September 25 report, including its good progress towards its goal to have $300 million annual revenue in FY27.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

“We are closing out the first half of the 2026 financial year pleased with the progress we have made,” Dr Atkinson explained today. “We continue to see broad-based growth led by our Australian and international businesses supporting our drive towards our $300 million target.”

He continued: “We have also made significant progress laying the foundations for future growth through our licensing operations and research and development programme. A key achievement in the current quarter is the result from the phase III clinical trial of our intravenous iron development project, which is targeting an addressable market worth US$7.41 billion.”

You can watch the full HotCopper Watchlist interview in the browser above.

Join the discussion. See what HotCopper users are saying about AFT Pharmaceuticals Ltd and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.